<DOC>
	<DOC>NCT02663908</DOC>
	<brief_summary>The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in patients with prostate cancer and cardiovascular disease.</brief_summary>
	<brief_title>A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Advanced prostate cancer Indication to initiate androgen deprivation therapy (ADT) Predefined cardiovascular disease Previous or current hormonal management of prostate cancer (unless terminated at least 12 months prior to trial) Acute cardiovascular disease in the previous 30 days Patients who are candidates for prostate cancer therapy with curative intention (e.g. prostatectomy, radiotherapy)</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>